Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.63), $0.09 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $171.41 million versus the consensus estimate of $169.83 million.

GUIDANCE:

Tandem Diabetes reaffirms FY2023 revenue of $885-900 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.